STAB Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 20:24):

Stats
Dagens volum	401.00
Gjennomsnittsvolum	24 991.00
Markedsverdi	49 991.00
EPS	$0 ( 2024-03-11 )
Neste inntjeningsdato	( $0 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-02-22	Chandrasekhar Satishchandran	Buy	0
2021-09-09	Saluck Randy S.	Buy	60 000	Common Stock, par value $0.005 per share
2021-09-09	Barbarick Steve K	Buy	60 000	Common Stock, par value $0.005 per share
2021-09-09	Verny Lea	Buy	60 000	Common Stock, par value $0.005 per share
2021-09-28	Markvicka Taunia	Buy	100 000	Common Stock, par value $0.005 per share

INSIDER POWER
0.00
Last 70 transactions
Buy: 2 421 695 \| Sell: 3 004 967

Statera Biopharma, Inc. Korrelasjon

10 Mest positive korrelasjoner
NAKD	0.946
AHPI	0.943
BHTG	0.935
TUEM	0.935
LGMK	0.932
MTEX	0.93
GRIN	0.923
AMGN	0.918
SMIT	0.917
PIII	0.917

10 Mest negative korrelasjoner
ALGM	-0.974
ATRS	-0.966
FRSG	-0.965
QIPT	-0.965
XPDB	-0.963
CRUS	-0.963
ITAQ	-0.963
VPCB	-0.962
NPAB	-0.961
ACQR	-0.961

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Statera Biopharma, Inc. Økonomi

Annual	2021
Omsetning:	$1.49M
Bruttogevinst:	$998 722 (67.16 %)
EPS:	$-2.90

FY	2021
Omsetning:	$1.49M
Bruttogevinst:	$998 722 (67.16 %)
EPS:	$-2.90

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.471

FY	2019
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.126

Financial Reports:

No articles found.

Statera Biopharma, Inc.

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.